Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. futures rose, but Alignment Healthcare plunged 24% after a Medicare contract downgrade; telecom and other stocks also fell premarket.
Stocks · News reference
Entera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meeting
Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia)These
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Entera Bio Ltd. (ENTX)
Filed: 2026-10-06 AccNo: 0001178913-26-004720 Size: 225 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11
Guggenheim analyst Vamil Divan initiates coverage on Entera Bio (NASDAQ:ENTX) with a Buy rating and announces Price Target of $11.